Want to see SMMT full AI Analyst Report?
SMMT Stock Chart & Stats
$25.15
$0.42(2.31%)
At close: 4:00 PM EST
$25.15
$0.42(2.31%)
Day’s Range― - ―
52-Week Range$12.55 - $30.98
Previous CloseN/A
Volume1.23M
Average Volume (3M)5.77M
Market Cap
$11.97B
Enterprise Value$10.84B
Total Cash (Recent Filing)$454.05M
Total Debt (Recent Filing)$15.20M
Price to Earnings (P/E)―
Beta2.99
Next Earnings
Aug 12, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.40
Shares Outstanding776,162,660
10 Day Avg. Volume7,344,858
30 Day Avg. Volume5,767,798
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)26.74
Price to Sales (P/S)0.00
P/FCF Ratio-54.45
Enterprise Value/Market Cap0.91
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-10.29
Forecast
1Y Price Target
$29.25Price Target Upside16.32% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering13
EPS Forecast (FY)-1.13
Revenue Forecast (FY)$3.85M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy (ivonescimab)Robust interim Phase II results materially de-risk the lead bispecific candidate by showing high response and durable control in first-line metastatic colorectal cancer. This strengthens the clinical thesis, improves probability of Phase III success, and increases partner/milestone optionality over the medium term.
Collaboration/licensing Revenue ModelSummit’s partnership/licensing model spreads development and commercialization risk while creating milestone and royalty revenue levers. Such deal-driven economics can provide non-dilutive or staged funding, extend runway, and align incentives with partners—supporting sustainable financing if clinical progress continues.
Comparatively Conservative LeverageLow leverage and a meaningful equity base give Summit flexibility to fund clinical programs and negotiate partnership terms without acute refinancing pressure. For a development-stage biotech, this balance sheet profile reduces short-term insolvency risk and provides optionality for strategic transactions or staged financings.
Bears Say
High Cash BurnRapidly increasing negative free cash flow signals substantial ongoing funding needs that will likely require external capital or material partner payments. Persistent burn elevates dilution risk, compresses runway if milestones slip, and increases the likelihood of financing-dependent delays or restructurings over the coming months.
No Commercial RevenueWith no product sales, Summit lacks operating leverage from commercial cash flow and remains binary on clinical/regulatory outcomes and partner milestones. This structural dependence on external funding and milestone timing raises long-term uncertainty about sustainable operations absent successful approvals or significant collaboration payments.
Share-based Dilution RiskExpanding the incentive share pool increases potential future dilution at a time of elevated financing need. While necessary for talent retention, larger equity compensation and ongoing at-the-market programs combined with fundraising needs could meaningfully dilute existing holders unless clinical progress translates into commensurate value creation.
Summit Therapeutics News
SMMT FAQ
What was Summit Therapeutics PLC’s price range in the past 12 months?
Summit Therapeutics PLC lowest stock price was $12.55 and its highest was $30.98 in the past 12 months.
What is Summit Therapeutics PLC’s market cap?
Summit Therapeutics PLC’s market cap is $11.97B.
When is Summit Therapeutics PLC’s upcoming earnings report date?
Summit Therapeutics PLC’s upcoming earnings report date is Aug 12, 2026 which is in 39 days.
How were Summit Therapeutics PLC’s earnings last quarter?
Summit Therapeutics PLC released its earnings results on Apr 30, 2026. The company reported -$0.24 earnings per share for the quarter, beating the consensus estimate of -$0.269 by $0.029.
Is Summit Therapeutics PLC overvalued?
According to Wall Street analysts Summit Therapeutics PLC’s price is currently Undervalued.
Does Summit Therapeutics PLC pay dividends?
Summit Therapeutics PLC does not currently pay dividends.
What is Summit Therapeutics PLC’s EPS estimate?
Summit Therapeutics PLC’s EPS estimate is -0.27.
How many shares outstanding does Summit Therapeutics PLC have?
Summit Therapeutics PLC has 776,162,660 shares outstanding.
What happened to Summit Therapeutics PLC’s price movement after its last earnings report?
Summit Therapeutics PLC reported an EPS of -$0.24 in its last earnings report, beating expectations of -$0.269. Following the earnings report the stock price went down -24.907%.
Which hedge fund is a major shareholder of Summit Therapeutics PLC?
Currently, no hedge funds are holding shares in SMMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Summit Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$29.25 (16.32% Upside)
$29.25 (16.32% Upside)
Blogger Sentiment
Neutral
SMMT Sentiment 50%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth $103.6M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 0.4%
Last 30 Days ▲ 1.0%
Last 30 Days ▲ 1.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.83%
12-Months-Change
Fundamentals
Return on Equity
-340.55%
Trailing 12-Months
Asset Growth
68.79%
Trailing 12-Months
Company Description
Summit Therapeutics PLC
Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.
SMMT Company Deck
SMMT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a strong set of clinical and operational achievements: multiple positive Phase III readouts, broad global development, robust patient exposure, strategic collaborations, a healthy cash balance ($713.4M), manufacturing transfer to the U.S., and an accepted BLA with a November 14, 2026 PDUFA date. Key risks remain around demonstrating statistically significant overall survival for U.S. approval in the EGFR setting, OS immaturity at the interim PFS readout for HARMONi-3 squamous, increased near-term R&D spending (non-GAAP op expenses +~9.6% Q/Q), and reliance on partner-generated data from China which may require bridging for global regulatory bodies. On balance, the highlights (clinical momentum, approvals in China, partnerships, cash runway, manufacturing readiness) outweigh the challenges, but the path to full U.S. approval and broader commercialization depends on forthcoming OS data and regulatory interactions.View all SMMT earnings summariesSMMT Stock 12 Month Forecast
Average Price Target
$29.25
▲(16.32% Upside)
Technical Analysis
Ownership Overview
Currently, No data available
---